Sign Up to like & get recommendations! 0
Published in 2018 at "Atherosclerosis"
DOI: 10.1016/j.atherosclerosis.2018.05.037
Abstract: BACKGROUND AND AIMS Familial hypercholesterolaemia (FH) is an autosomal dominant lipoprotein disorder characterized by significant elevation of low-density lipoprotein cholesterol (LDL-C) and markedly increased risk of premature cardiovascular disease (CVD). Because of the very high… read more here.
Sign Up to like & get recommendations! 0
Published in 2021 at "Scientific Reports"
DOI: 10.1038/s41598-021-83392-w
Abstract: Familial hypercholesterolaemia increases circulating LDL-C levels and leads to premature cardiovascular disease when undiagnosed or untreated. Current guidelines support genetic testing in patients complying with clinical diagnostic criteria and cascade screening of their family members.… read more here.
Sign Up to like & get recommendations! 0
Published in 2021 at "Xenobiotica"
DOI: 10.1080/00498254.2021.1945165
Abstract: Abstract Statins, the standard treatment for hypercholesterolaemia, among the most widely prescribed, have been associated with side effects, including statin intolerance. The aim of this study was to determine the background prevalence of SLCO1B1 SNVs… read more here.
Sign Up to like & get recommendations! 0
Published in 2024 at "International Journal of Circumpolar Health"
DOI: 10.1080/22423982.2024.2386783
Abstract: ABSTRACT The anthropometric index that best predicts cardiometabolic risk remains inconclusive. This study therefore assessed the prevalence of obesity using six indices and compared their associations with obesity-related cardiometabolic disorders. We determined obesity prevalence according… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "European journal of preventive cardiology"
DOI: 10.1093/eurjpc/zwac200
Abstract: Familial hypercholesterolaemia (FH) is under-recognized and under-treated in Europe leading to significantly higher risk for premature heart disease in those affected. As treatment beginning early in life is highly effective in preventing heart disease and… read more here.
Sign Up to like & get recommendations! 0
Published in 2019 at "Current Opinion in Lipidology"
DOI: 10.1097/mol.0000000000000584
Abstract: DOI:10.1097/MOL.0000000000000584 Familial hypercholesterolaemia is an autosomal dominant disorder of lipid metabolism characterized by elevated levels of LDL-C and increased cardiovascular risk. Although the disorder can be diagnosed based on established clinical criteria, only the genetic… read more here.
Sign Up to like & get recommendations! 0
Published in 2017 at "Journal of Paediatrics and Child Health"
DOI: 10.1111/jpc.13457
Abstract: To determine whether information about a family history of hypercholesterolaemia or early cardiovascular disease was documented by paediatricians in children and adolescents with elevated low‐density lipoprotein (LDL)‐cholesterol levels. read more here.
Sign Up to like & get recommendations! 0
Published in 2025 at "BMJ Case Reports"
DOI: 10.1136/bcr-2024-263538
Abstract: Familial hypercholesterolaemia (FH) is a common yet underdiagnosed genetic disorder of low-density lipoprotein metabolism leading to premature cardiovascular disease. Most FH individuals are only diagnosed later in their adulthood, missing the critical window for pre-emptive… read more here.
Sign Up to like & get recommendations! 0
Published in 2019 at "Annals of Clinical Biochemistry"
DOI: 10.1177/0004563218793165
Abstract: Background and aim Familial hypercholesterolaemia is caused by variants in the low-density lipoprotein cholesterol metabolic pathway involving LDLR, APOB and PCSK9 genes. A national genetic testing service in Wales, UK has observed that no familial… read more here.
Sign Up to like & get recommendations! 0
Published in 2019 at "Journal of Medical Screening"
DOI: 10.1177/0969141318796856
Abstract: Objective To integrate child–parent screening and cascade testing into a single pathway-child-parent cascade screening (CPCS), for the identification of familial hypercholesterolaemia in the population and to estimate the number of new familial hypercholesterolaemia cases identified… read more here.
Sign Up to like & get recommendations! 0
Published in 2019 at "PLoS ONE"
DOI: 10.1371/journal.pone.0210373
Abstract: Background Hypercholesterolaemia is common in patients after cardiac transplantation. Monoclonal antibodies that inhibit proprotein convertase subtilisin-kexin type 9 (PCSK9) reduce low-density lipoprotein (LDL) cholesterol levels and subsequently the risk of cardiovascular events in patients with… read more here.